After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The cash-challenged biotech firm specializing in BsAbs and immuno-oncology therapies is turning to a Hong Kong listing to try to replenish its coffersKey Takeaways:YZY Biopharma has filed for a Hong…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US - InSilico seeks IPO boost to get AI drugs over the line
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
ANL.US
